Last reviewed · How we verify
NCT05525806
Clinical Utility Study for MyProstateScore+
NA trial testing Education Materials for MyProstateScore in Prostate Cancer in 234 participants. Completed in 4 June 2023.
4 June 2023
Quick facts
| Lead sponsor | Qure Healthcare, LLC |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 234 |
| Start date | 12 September 2022 |
| Primary completion | 4 June 2023 |
| Estimated completion | 4 June 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Education Materials for MyProstateScore
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Qure Healthcare, LLC — full company profile →
Who can join
Eligibility, any sex, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a national-level research study of urologists. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care indications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05525806
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Qure Healthcare, LLC trials
Trials by the same sponsor.
- NCT07099001 — Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay · NA · completed
- NCT05702385 — Clinical Utility Study for Exo-PDAC · NA · withdrawn
- NCT05603299 — Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test · NA · withdrawn
- NCT05910697 — Clinical Utility of MyProstateScore 2.0 P2 · NA · terminated
- NCT05658653 — Clinical Utility of CDMT Among VillageMD Providers · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05525806 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qure Healthcare, LLC
- Last refreshed: 13 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05525806.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing